Benchmark Has Lowered Expectations for Harvard Bioscience (NASDAQ:HBIO) Stock Price

Harvard Bioscience (NASDAQ:HBIO) had its target price lowered by Benchmark from $5.50 to $4.50 in a note issued to investors on Monday,Benzinga reports. The brokerage currently has a “speculative buy” rating on the medical instruments supplier’s stock.

Harvard Bioscience Stock Down 1.1 %

Shares of Harvard Bioscience stock opened at $0.59 on Monday. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.91 and a current ratio of 2.06. Harvard Bioscience has a 52-week low of $0.56 and a 52-week high of $4.70. The company’s 50 day moving average price is $1.22 and its 200-day moving average price is $1.95. The stock has a market capitalization of $26.10 million, a price-to-earnings ratio of -1.79 and a beta of 1.46.

Hedge Funds Weigh In On Harvard Bioscience

Several hedge funds and other institutional investors have recently modified their holdings of HBIO. GSA Capital Partners LLP bought a new position in Harvard Bioscience during the 3rd quarter valued at approximately $30,000. Avior Wealth Management LLC increased its stake in shares of Harvard Bioscience by 1,118.1% during the third quarter. Avior Wealth Management LLC now owns 14,569 shares of the medical instruments supplier’s stock valued at $39,000 after buying an additional 13,373 shares during the period. Connor Clark & Lunn Investment Management Ltd. raised its holdings in shares of Harvard Bioscience by 19.7% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 180,006 shares of the medical instruments supplier’s stock valued at $484,000 after acquiring an additional 29,607 shares in the last quarter. Landscape Capital Management L.L.C. purchased a new stake in Harvard Bioscience in the third quarter worth $50,000. Finally, Advantage Alpha Capital Partners LP bought a new stake in Harvard Bioscience in the third quarter valued at $64,000. 80.87% of the stock is owned by institutional investors.

About Harvard Bioscience

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.